Eli Lilly & Co. has agreed to pay $18.5 million to the State of Arkansas to settle a lawsuit alleging that the company engaged in “illegal and fraudulent off-label marketing of Zyprexa,” an anti-psychotic drug.

The company allegedly promoted the drug for a variety of unapproved uses, including treatment of dementia, aggression, depression and sleep disorders, as well as use in children.

The Arkansas state Medicaid trust fund will receive the bulk of the settlement, $15 million.